Open AccessDrug therapy for COVID-19 inpatients in West Nusa Tenggara hospital
Author(s) -
Mahacita Andanalusia,
Shah Iqbal Ikraman Akbar,
Anna Pradiningsih
Publication year - 2022
Publication title -
pharmacy education
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.198
H-Index - 17
eISSN - 1477-2701
pISSN - 1560-2214
DOI - 10.46542/pe.2022.222.180183
Subject(s) - medicine , azithromycin , covid-19 , medical record , drug , pharmacotherapy , antibiotics , adjuvant therapy , oseltamivir , pharmacology , infectious disease (medical specialty) , chemotherapy , disease , microbiology and biotechnology , biology
Background: COVID-19 represents an unprecedented challenge to the world. Various attempts have been made to overcome COVID-19, including employing multiple drug therapies.Objective: This study was conducted to describe the drug therapy of COVID-19 inpatients at the West Nusa Tenggara Hospital in 2020.Methods: Observation of 102 patients was conducted retrospectively. Data collection was performed by analysing medical records.Results: A total of 62 out of the 102 patients (60.8%) were hospitalised more than four weeks. 57 patients (55.9%) received antivirus therapy with Oseltamivir and 47 patients (46.1%) recieved azithromycin as adjuvant antibiotic therapy. Most of the patients (63.7%) received vitamin C as an immunomodulator. A small number of patients received other supportive therapies recommended to decrease the symptoms of COVID-19. The most frequent administered therapies for COVID-19 patients hospitalised at the West Nusa Tenggara Hospital are antivirals, antibiotics, and immunomodulators.Conclusion: The findings provide an overview of therapy use for COVID-19 inpatients in West Nusa Tenggara Hospital. There is a need to assess the effectiveness of the therapy to promote safe and effective use of drugs for COVID-19 patients in the future.